Erschienen in:
01.05.2014 | Gastrointestinal Oncology
Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States
verfasst von:
K. Turaga, E. Levine, R. Barone, R. Sticca, N. Petrelli, L. Lambert, G. Nash, M. Morse, R. Adbel-Misih, H. R. Alexander, F. Attiyeh, D. Bartlett, A. Bastidas, T. Blazer, Q. Chu, K. Chung, L. Dominguez-Parra, N. J. Espat, J. Foster, K. Fournier, R. Garcia, M. Goodman, N. Hanna, L. Harrison, R. Hoefer, M. Holtzman, J. Kane, D. Labow, B. Li, A. Lowy, P. Mansfield, E. Ong, C. Pameijer, J. Pingpank, M. Quinones, R. Royal, G. Salti, A. Sardi, P. Shen, J. Skitzki, J. Spellman, J. Stewart, J. Esquivel
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 5/2014
Einloggen, um Zugang zu erhalten
Abstract
Background
The American Society of Peritoneal Surface Malignancies (ASPSM) is a consortium of cancer centers performing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). This is a position paper from the ASPSM on the standardization of the delivery of HIPEC.
Methods
A survey was conducted of all cancer centers performing HIPEC in the United States. We attempted to obtain consensus by the modified method of Delphi on seven key HIPEC parameters: (1) method, (2) inflow temperature, (3) perfusate volume, (4) drug, (5) dosage, (6) timing of drug delivery, and (7) total perfusion time. Statistical analysis was performed using nonparametric tests.
Results
Response rates for ASPSM members (n = 45) and non-ASPSM members (n = 24) were 89 and 33 %, respectively. Of the responders from ASPSM members, 95 % agreed with implementing the proposal. Majority of the surgical oncologists favored the closed method of delivery with a standardized dual dose of mitomycin for a 90-min chemoperfusion for patients undergoing cytoreductive surgery for peritoneal carcinomatosis of colorectal origin.
Conclusions
This recommendation on a standardized delivery of HIPEC in patients with colorectal cancer represents an important first step in enhancing research in this field. Studies directed at maximizing the efficacy of each of the seven key elements will need to follow.